Emergent Biosolutions EBS Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances?
- Emergent Biosolutions (EBS) reported proceeds from exercises of stock options and other stock issuances of $0 in Q1 2026.
- How has Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances decreased by 100.0% year-over-year, from $100K to $0.
- What is the long-term trend for Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Emergent Biosolutions's proceeds from exercises of stock options and other stock issuances has grown at a -100.0% compound annual growth rate (CAGR), from $15.9M to $0.